Abeona Therapeutics (ABEO) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 3.2% versus a loss of 60.3%. Over five years, ABEO leads with a -77.7% price change compared with -85.9% for FULC. Fulcrum Therapeutics is the larger company by market cap ($286.1 million vs $283.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | FULC |
|---|---|---|
| Share price | $4.96 | $3.75 |
| Market cap | $283.63M | $286.11M |
| 1-day change | -2.36% | +2.18% |
| YTD return | -3.61% | -67.55% |
| 1-year return | -3.24% | -60.28% |
| 5-year return | -77.67% | -85.88% |
| EPS (TTM) | $-1.18 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $15.74 |
| 52-week low | $4.00 | $2.83 |
| Distance from 52-week high | -35.16% | -76.18% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +280.65% | -2.13% |
| Average volume | 1.41M | 1.53M |
| Shares outstanding | 57.18M | 76.30M |
| Employees | 226 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed FULC by 57.0 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ABEO vs FULC FAQ
Which is bigger, Abeona Therapeutics or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $286.11M compared with $283.63M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or FULC?
ABEO returned -3.24% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.